CINCINNATI — Researchers at Cincinnati Children's Hospital Medical Center published a study in the journal Gene Therapy on July 14, 2026, demonstrating that gene therapy restored expression of the FMRP protein and reversed multiple symptoms of fragile X syndrome in mouse models. The findings suggest that key neurological deficits associated with the disorder may be treatable even after early brain development has largely concluded.

The study tested adeno-associated viral vectors carrying the human FMR1 gene, which is normally silenced in individuals with fragile X syndrome. This gene therapy approach successfully produced the FMRP protein in key brain regions of Fmr1 knockout mice—animals genetically engineered to lack the FMR1 gene and display symptoms mirroring those seen in humans with the condition.

Gene therapy improved multiple phenotypes in the Fmr1 knockout mice. These improvements included reduced susceptibility to audiogenic seizures, which are seizures triggered by loud sounds and commonly observed in fragile X patients. The treated mice also showed improvements in sensory hyperactivity and exhibited less repetitive digging behavior, both of which are recognized behavioral markers of the syndrome in animal models.

Additionally, the therapy normalized elevated low-gamma EEG power in the mice. This brain activity pattern has been documented in human fragile X studies, reinforcing the relevance of the mouse findings to potential human applications. The results support the use of EEG measures as biomarkers that could bridge animal studies and future human clinical trials for fragile X syndrome.

Ernest Pedapati, MD, MS, a co-corresponding author of the study, said, "Our studies show that re-expression of FMRP in mice at ages equivalent to 4-6 and 15-30 years in humans has the potential to rescue sensory hypersensitivity, stereotypic behavior, and excessive EEG gamma power." He added, "This suggests that certain FXS-related deficits are reversible or can be improved by re-expression of FMRP after large parts of brain development have already occurred."

The gene therapy showed benefits when delivered at different age points in the mice, indicating that treatment timing may be flexible. The study also explored delivery routes, promoters, dosing strategies, and other factors critical to optimizing fragile X gene therapy. It details two administration pathways that could be combined to ensure the therapy reaches all key parts of the brain.

Fragile X syndrome is the most common inherited form of intellectual disability and a leading single-gene condition associated with autism. There is no cure for the disorder, and current care focuses on managing symptoms such as anxiety, sensory sensitivity, hyperactivity, developmental seizures, and learning challenges. The FMR1 gene is silenced in fragile X syndrome, leading to the absence of FMRP—a protein essential for regulating synaptic function and brain development.

The study, titled FMR1 gene therapy restores translationally relevant phenotypes in a mouse model for fragile X syndrome, was led by investigators at Cincinnati Children's Hospital Medical Center and collaborators at Forge Biologics. It has the DOI 10.1038/s41434-026-00630-4. R. K. Lacher is listed as an author of the paper.

Four co-corresponding authors contributed to the research: Christina Gross, PhD, a researcher in the Division of Neurology at Cincinnati Children's Hospital; Craig Erickson, MD, MA; Ernest Pedapati, MD, MS; and Durgesh Tiwari, PhD, M.Pharm. Their collaborative effort represents a step toward a potential disease-modifying therapy for fragile X syndrome.

The gene therapy approach has not yet been tested in people. More research is needed to evaluate safety, durability, dosing, immune responses, and the optimal timing for treatment in humans before clinical trials can begin.

Fragile X syndrome affects approximately 1 in 4,000 males and 1 in 8,000 females, with no approved therapies that address its underlying genetic cause. Current interventions are limited to symptom management, leaving families seeking more effective options. This study provides preclinical evidence that restoring FMRP—even after early developmental windows—can reverse core symptoms in a validated animal model, challenging assumptions that such deficits are fixed after brain maturation.

The identification of EEG biomarkers like low-gamma power offers a measurable, objective pathway to translate findings from mice to humans. If future studies confirm safety and efficacy in people, this gene therapy could represent the first treatment to modify the course of fragile X syndrome, potentially improving quality of life for thousands of affected individuals and their families.